# ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

> **NCT07320326** · — · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 159 (estimated)

## Conditions studied

- TCE-RRMM

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT07320326
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2028-07-18
- **Final completion:** 2028-09-18
- **Target enrollment:** 159 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07320326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07320326, "ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07320326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*